Maruti Suzuki Q4 Review - Strong Product Pipeline, Healthy Order Book: Reliance Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Reliance Securities Report.Maruti Suzuki India Ltd. delivered a very strong performance in Q4 FY22 as its Ebitda margin stood at 9.1% (versus our estimate of 8.1%). Revenue increased by 11% YoY to Rs 267.4 billion, slightly lower than our estimate of Rs 268.7 billion. Revenue growth was led by average selling price growth of 12% YoY and 1% QoQ to Rs 547,020 despite volume de-growth of 1% YoY.Ebitda came in at Rs 24.3 billion, versus our estimate of Rs 15.2 billion due to better cost control and improved pricing.Its profit after tax increased by 58% YoY to Rs 18.4 billion as against our estimate of Rs 15.2 billion, due to the better-than-expected operating performance. We believe that the better product-mix, likely ease on production, price hike and stable raw material environment would support Maruti Suzuki’s margin expansion, going forward, though near-term issue related supply constraints and commodity inflation is inevitable. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Maruti Suzuki Q4 Review - Strong Product Pipeline, Healthy Order Book: Reliance Securities

Maruti Suzuki Q4 Review - Strong Product Pipeline, Healthy Order Book: Reliance Securities

Choose a plan